Brightgene Bio-medical Technology Co. Ltd. Class ASSE: 688166

Announcement on Voluntary Disclosure of BGM1812 Injection Obtaining US. FDA Approval for Drug Clinical Trial

· Issued by Brightgene Bio-medical Technology Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of BGM1812 Injection Obtaining US. FDA Approval for Drug Clinical Trial

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment